Author

K. Reilly

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. A. Melcher· 1 shared A. Droop· 1 shared A. K. Meeker· 1 shared C. A. Pratilas· 1 shared C. Davis· 1 shared C. G. Eberhart· 1 shared C. M. Heaphy· 1 shared E. B. Wilson· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. A. Melcher

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Therapeutic vulnerability to ATR inhibition in concurrent NF1 and ATRX-deficient high-grade solid tumors

M. Yuan, C. G. Eberhart, C. A. Pratilas, J. O. Blakeley, C. Davis, M. Stojanova, K. Reilly, A. K. Meeker, C. M. Heaphy, F. J. Rodriguez

This study shows that combining NF1 and ATRX deficiency makes certain solid tumors vulnerable to ATR inhibition, especially those with alternative lengthening of telomeres.

bioRxiv · Feb 3, 2022 · PreprintCancer Biology

Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered natural killer cell phenotype in glioblastoma

H. J. Close, L. F. Stead, J. Nsengimana, K. Reilly, A. Droop, H. Wurdak, R. K. Mathew, R. Corns, J. A. Newton-Bishop, A. A. Melcher, S. C. Short, G. P. Cook, E. B. Wilson

bioRxiv · Oct 4, 2019Immunology